Copyright © Inderes 2011 - present. All rights reserved.
  • Uusimmat
  • Pörssi
    • Aamukatsaus
    • Osakevertailu
    • Pörssikalenteri
    • Osinkokalenteri
    • Analyysi
    • Artikkelit
    • Sisäpiirin kaupat
  • inderesTV
  • Mallisalkku
  • Foorumi
  • Premium
  • Femme
  • Opi
    • Sijoituskoulu
    • Q&A
    • Analyysikoulu
  • Meistä
    • Seurantayhtiöt
    • Tiimi
Pörssitiedote

IDL Diagnostics nomination committee for the AGM 2026

IDL Diagnostics
Lataa tiedote

IDL Diagnostics AB (publ.) publishes the nomination committee’s composition for the AGM in 2026.

The nomination committee, which is appointed in accordance with the principles adopted by the annual general meeting on May 15th, 2025, consists of:

  • Jerker Swanstein, (chairman of the nomination committee), representing Labbex Förvaltnings AB
  • Jon Eiken, representing own shares
  • Didrik Hamilton, representing own shares

Before the annual general meeting 2026, the nomination committee shall prepare a proposal for the election of the chairman and other members of the board of directors, the election of the chairman of the annual meeting, the election of auditors, the determination of fees, and matters pertaining to it.
 
For more information, please visit:
Nomination committee - IDL Diagnostics
 
Shareholders who wish to submit proposals to the nomination committee for the annual general meeting 2026 can e-mail info@idldiagnostics.com  (header ” IDL Diagnostics’ nomination committee”) or via letter to:

IDL Diagnostics AB
Att: Valberedning
P.O Box 11151
SE-161 11 Bromma
Sweden

The proposals should be submitted to the nomination committee before January 31st, 2026.

Contacts


Anders Hultman, CEO
Phone: +46 (0) 8 799 67 50
E-mail: anders.hultman@idldiagnostics.com

About IDL Diagnostics


IDL Diagnostics AB (publ) is a Swedish company that develops and markets blood and urine sample tests. The corporation specializes in oncology and bacteriology. The company has a broad product portfolio, used in healthcare, and established in various markets. In oncology, IDL Diagnostics uses various biomarkers, TK1, and cytokeratins, to support the treatment of various cancers such as breast, prostate, and bladder cancers. IDL Diagnostics' product portfolio also includes a rapid bacteriological test for a simple and safe diagnosis of typhoid fever. IDL Diagnostics (IDLDX) is listed on Nasdaq First North Growth Market with Redeye AB as company's Certified Adviser. For more information; www.idldiagnostics.com

Attachments


IDL Diagnostics nomination committee for the AGM 2026

Sosiaalinen media
  • Inderes Foorumi
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Yhteystiedot
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • Meistä
  • Tiimi
  • Avoimet työpaikat
  • Inderes sijoituskohteena
  • Palvelut pörssiyhtiöille
Sivusto
  • UKK
  • Käyttöehdot
  • Tietosuojaseloste
  • Vastuuvapauslauseke
Inderesin vastuuvapauslauseke löytyy täältä. Kunkin Inderesin aktiivisessa seurannassa olevan osakkeen tarkemmat tiedot löytyvät kunkin osakkeen omilta yhtiösivuilta Inderes-sivustolla. © Inderes Oyj. Kaikki oikeudet pidätetään.